Refractive changes after intravitreal ranibizumab injections for diabetic macular oedema

2017 ◽  
Vol 101 (3) ◽  
pp. 397-399
Author(s):  
Irini Chatziralli ◽  
Athanasios Chatzipantelis ◽  
Eleni Dimitriou ◽  
Evgenia Mpourouki ◽  
George Theodossiadis ◽  
...  
Keyword(s):  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Intravitreal Ranibizumab

scholarly journals Clinically meaningful visual improvements and predictors of early vision gains with ranibizumab for diabetic macular oedema

2019 ◽  
Vol 4 (1) ◽  
pp. e000335
Author(s):  
Lawrence Morse ◽  
Linda Yau ◽  
Lisa Tuomi
Keyword(s):  
Macular Oedema ◽  
Subretinal Fluid ◽  
Diabetic Macular Oedema ◽  
Phase Iii ◽  
Early Vision ◽  
Intravitreal Ranibizumab ◽  
Meaningful Improvement ◽  
Link Type ◽  
Kaplan Meier ◽  
Younger Age

ObjectiveTo determine the time to first clinically meaningful improvement in best-corrected visual acuity (BCVA) in patients treated with ranibizumab for diabetic macular oedema (DME) and identify predictors of early visual improvement.Methods and analysisWe retrospectively analysed the phase III RIDE (NCT00473382) and RISE (NCT00473330) trials, in which 759 patients with DME were randomised to monthly intravitreal ranibizumab 0.3 mg (n=250), ranibizumab 0.5 mg (n=252) or sham treatment (n=257). After month 24, 191 sham-treated patients crossed over to monthly ranibizumab 0.5 mg through month 36, while ranibizumab-treated patients continued treatment. Kaplan-Meier analyses assessed time to achieve ≥15 or ≥10 Early Treatment Diabetic Retinopathy Study (ETDRS) letter gains from baseline or ≥20/40 Snellen equivalent BCVA in each treatment arm. Baseline predictors of ≥15 ETDRS letter gains at month 6 were identified by logistic regression.ResultsMedian time to first ≥15 ETDRS letter gain was significantly shorter in patients who received ranibizumab (0.3 mg, 11.1 months; 0.5 mg, 10.9 months) than sham-treated patients who crossed over to ranibizumab 0.5 mg at month 24 (35.7 months; both p<0.0001). Half of ranibizumab-treated patients achieved ≥20/40 BCVA within 2.3 (0.3 mg) and 1.9 months (0.5 mg). Baseline predictors of early vision improvement among ranibizumab-treated patients were BCVA ≤55 ETDRS letters, younger age and presence of subretinal fluid.ConclusionPrompt ranibizumab therapy for DME was associated with rapid, clinically meaningful vision gains that were maintained over 36 months of treatment. Lower BCVA, younger age and presence of subretinal fluid were predictive of early vision improvement.

scholarly journals Intravitreal ranibizumab for diabetic macular oedema in previously vitrectomized eyes

2016 ◽  
Vol 95 (1) ◽  
pp. 28-32 ◽  
Author(s):  
Caroline Schmidt Laugesen ◽  
Christoffer Ostri ◽  
Troels Brynskov ◽  
Henrik Lund-Andersen ◽  
Michael Larsen ◽  
...  
Keyword(s):  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Intravitreal Ranibizumab

scholarly journals Influence of baseline diabetic retinopathy status on initial anatomical response of intravitreal ranibizumab therapy for diabetic macular oedema

Eye ◽  
2017 ◽  
Vol 31 (9) ◽  
pp. 1358-1364 ◽  
Author(s):  
L Nicholson ◽  
N V Patrao ◽  
J Ramu ◽  
C Vazquez-Alfageme ◽  
M Muwas ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Intravitreal Ranibizumab

Microperimetry and mfERG as functional measurements in diabetic macular oedema undergoing intravitreal ranibizumab treatment

Eye ◽  
2020 ◽  
Author(s):  
Ana Rita Santos ◽  
Miguel Raimundo ◽  
Dalila Alves ◽  
Marta Lopes ◽  
Sérgio Pestana ◽  
...  
Keyword(s):  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Intravitreal Ranibizumab ◽  
Ranibizumab Treatment

scholarly journals Aqueous humour cytokine changes during a loading phase of intravitreal ranibizumab or dexamethasone implant in diabetic macular oedema

2019 ◽  
Vol 98 (4) ◽  
Author(s):  
Dominika Podkowinski ◽  
Eva Orlowski‐Wimmer ◽  
Gerhard Zlabinger ◽  
Andreas Pollreisz ◽  
Anna‐Sophie Mursch‐Edlmayr ◽  
...  
Keyword(s):  
Macular Oedema ◽  
Aqueous Humour ◽  
Diabetic Macular Oedema ◽  
Dexamethasone Implant ◽  
Intravitreal Ranibizumab

Effect of intravitreal ranibizumab injection on aqueous humour cytokine levels in patients with diabetic macular oedema

2016 ◽  
Vol 95 (4) ◽  
pp. e340-e341 ◽  
Author(s):  
Tomoyasu Shiraya ◽  
Satoshi Kato ◽  
Fumiyuki Araki ◽  
Takashi Ueta
Keyword(s):  
Macular Oedema ◽  
Aqueous Humour ◽  
Diabetic Macular Oedema ◽  
Intravitreal Ranibizumab ◽  
Cytokine Levels

scholarly journals Symmetry in early response to intravitreal ranibizumab in bilateral diabetic macular oedema

2015 ◽  
Vol 94 (5) ◽  
pp. e356-e360 ◽  
Author(s):  
Margaux Guillard ◽  
Bénédicte Dupas ◽  
Mohamed El Sanharawi ◽  
Ali Erginay ◽  
Ramin Tadayoni ◽  
...  
Keyword(s):  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Early Response ◽  
Intravitreal Ranibizumab

Intravitreal ranibizumab for diabetic macular oedema: 1-year experiences in a clinical setting

2012 ◽  
Vol 91 (3) ◽  
pp. e243-e244 ◽  
Author(s):  
Troels Brynskov ◽  
Caroline Schmidt Laugesen ◽  
Torben Lykke Sørensen
Keyword(s):  
Clinical Setting ◽  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Intravitreal Ranibizumab

scholarly journals Intravitreal Ranibizumab for Diabetic Macular Oedema

2015 ◽  
Vol 09 (01) ◽  
pp. 32 ◽  
Author(s):  
Francesco Bandello ◽  
Maria Vittoria Cicinelli ◽  
Maurizio Battaglia Parodi ◽  
◽  
◽  
...  
Keyword(s):  
Macular Oedema ◽  
Vision Loss ◽  
Diabetic Macular Oedema ◽  
Standard Of Care ◽  
Vascular Endothelial ◽  
Intravitreal Ranibizumab ◽  
Remarkable Effect ◽  
The Past ◽  
Endothelial Growth Factor ◽  
Ranibizumab Treatment

Diabetic macular oedema (DMO) is the most frequent cause of vision loss in patients affected by diabetes mellitus, and has a remarkable effect on public health. The treatment with focal/grid laser photocoagulation was considered in the past decades as the standard of care, but the recent advent of new pharmacological approaches, based on the use of intravitreal anti-vascular endothelial growth factor (anti-VEGF), has completely revolutionised the management of DMO. The most important molecule of this class of drugs is represented by ranibizumab, which has been clinically supported by several randomised clinical trials. The present review aims at providing a comprehensive summary of the most important investigations regarding the ranibizumab treatment of DMO.

Sign in / Sign up

Export Citation Format

Share Document